South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Frontier Medicines is raising $88,499,972.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Chris Varma played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Frontier Medicines
Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers of disease. Our lead program targets both the activated and inactive forms of KRAS G12C, a validated driver in a number of cancers that until recently has been undruggable. Our pipeline embodies our vision of bolding advancing science to defeat disease, starting with cancer.

To learn more about Frontier Medicines, visit http://frontiermeds.com/

Contact:
Chris Varma, Chief Executive Officer
650-457-1005
chris@frontiermeds.com
https://www.linkedin.com/in/chris-varma-59828a4/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved